ST. LOUIS, Nov. 26, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Chief Executive Officer, is scheduled to present at the 11th Annual LD Micro Main Event investor conference. Mr. Fischel […]
Tag: Stereotaxis
Stereotaxis Reports 2018 Third Quarter Financial Results
ST. LOUIS, Nov. 12, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2018. “We continue to make meaningful progress on our strategic innovation initiatives, and expect […]
Stereotaxis to Report Third Quarter 2018 Financial Results on November 12, 2018
ST. LOUIS, Nov. 02, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 third quarter ended September 30, 2018 on Monday, November 12, 2018 before the open […]
Stereotaxis to Present at OTCQX Virtual Investor Conference for Domestic Companies
ST. LOUIS, Mo., Sept. 25, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will present at the OTCQX Virtual Investor Conference for Domestic Companies. Management will provide an overview of the Company’s technology […]
Stereotaxis Reports 2018 Second Quarter Financial Results
ST. LOUIS, Aug. 07, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2018. “The second quarter was notable for the strategic agreements announced with Johnson & […]
Stereotaxis to Report Second Quarter 2018 Financial Results on August 7, 2018
ST. LOUIS, July 31, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 second quarter ended June 30, 2018 on Tuesday, August 7, 2018 before the open of […]
Stereotaxis and Johnson & Johnson’s Biosense Webster Extend Development Alliance and Supply Agreement
ST. LOUIS, June 25, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it has entered into an amendment to the long-term Development Alliance and Supply Agreement with Johnson & Johnson’s Biosense Webster, Inc. The amendment […]
Stereotaxis Announces Changes to its Board of Directors
ST. LOUIS, June 04, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Ross B. Levin to its board of directors. Mr. Levin is the Director of Research at Arbiter Partners, a successful New […]
Stereotaxis to Present at 8th Annual LD Micro Invitational
ST. LOUIS, May 22, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Chief Executive Officer, is scheduled to present at the 8th Annual LD Micro Invitational. Mr. Fischel will provide an […]
Stereotaxis’ Leadership in Robotic Cardiac Ablation to be Showcased at Heart Rhythm 2017 and First Annual Meeting of Society for Cardiac Robotic Navigation (Americas)
ST. LOUIS, April 25, 2017 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the annual Heart Rhythm Society (HRS) Scientific Sessions at McCormick Place in Chicago from May 10-13. With a message […]
Recent
Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
Bunkerhill Health and Cleerly Announce Strategic Partnership to Advance Noninvasive Cardiovascular Care
Popular
- No commented posts yet